Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC

Lorlatinib is a promising third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been approved for treating ALK-positive non-small-cell lung cancer (NSCLC) patients with previous ALK-TKI treatment failures. However, the inevitable emergence of acquired resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Conghua, Yu, Rui, Zhang, Chong, Lin, Caiyu, Dou, Yuanyao, Wu, Di, Pan, Yonghong, Peng, Tao, Tang, Huan, Han, Rui, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033765/
https://www.ncbi.nlm.nih.gov/pubmed/35459209
http://dx.doi.org/10.1038/s41420-022-01027-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033765/
https://www.ncbi.nlm.nih.gov/pubmed/35459209
http://dx.doi.org/10.1038/s41420-022-01027-z

Ejemplares similares